The team at Children’s Hospital Boston and the Harvard Stem Cell Institute were working with a new type of cell called induced pluripotent stem cells or iPS cells, which closely resemble embryonic stem cells but are made from ordinary skin cells.
In this case, they wanted to study a rare, inherited premature aging disorder called dyskeratosis congenita. The blood marrow disorder resembles the better-known aging disease progeria and causes premature graying, warped fingernails and other symptoms as well as a high risk of cancer.
One of the benefits of stem cells and iPS cells is that researchers can make them from
BioTime Inc, a biotechnology company that develops and markets products in the field of regenerative medicine, and its subsidiaries OrthoCyte Corporation and LifeMap Sciences reported today a means of manufacturing seven distinct types of cartilage, bone, and tendon cells from human embryonic stem cells. The paper, scheduled to be published online (ahead of print) at 1600 GMT today in the peer-reviewed journal Regenerative Medicine, characterizes the seven cell types generated using BioTime’s proprietary PureStem(TM) technology. The study compared the novel cells with adult stem cells, known as mesenchymal stem cells (MSCs), and revealed properties of the new cell lines
Ten years ago, Leah Potts was a patient at Craig Hospital, after a skiing accident that broke her neck and damaged her spinal cord. The first doctors she saw warned her she might never walk again.
Today, Potts teaches Spinning, the popular and intense indoor group bicycling class. The Aspen resident can walk (with a cane). She skis again (with outriggers). And she blogs about her progress at leahpotts.com.
“I remember lying there in bed at the beginning,” she said. “I remember lying there thinking, ‘OK, this doesn’t sound too good. I have two choices: Lie here and cry about it,
Image via Wikipedia
Summit at Lake Como with 100 European stem cell experts.
At the summit, 16 research teams part of the Neurostemcell consortium that have been working for months on finding treatments for Parkinson’s and Huntington’s disease met. The network, coordinated by Elena Cattaneo, Director of Unistem, the interdepartmental stem cell research centre of the University of Milan, met on April 1 in Bellagio, on the shores of Lake Como for their first annual meeting.
“The meeting is an opportunity to discuss the results obtained until now and to refine our methods,” explained Cattaneo, who pointed out the objective of
Image via Wikipedia
Scientists may be growing impatient, but President Obama has been rightly taking his time in addressing a campaign promise to lift the ban on federal funding for research using new lines of stem cells to be taken from human embryos. Even for strong backers of embryonic stem cell research, the decision is no longer as self-evident as it was, because there is markedly diminished need for expanding these cell lines for either patient therapy or basic research. In fact, during the first six weeks of Obama’s term, several events reinforced the notion that embryonic stem cells, once